ArticleFolia microbiologica2025
Comparative assessment of antibacterial, antifungal, and cytotoxic activities of ceragenins CSA-44 and CSA-131 against endodontic pathogens.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cationic steroid antimicrobials (CSA-ceragenin), which includes CSA44 and CSA 131, constitute a novel family of antimicrobial drugs. This study aims to examine the antibacterial and antifungal properties of CSA-44 and CSA-131 against Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), Enterococcus faecalis, and Candida albicans. Additionally, the cytotoxic effects of both compounds were addressed using dental pulp stem cell lines. The CSA-44 compound with a concentration of 0.05% yielded the lowest minimum inhibitory concentration (MIC) of 0.04 µg/mL against E. faecalis. The minimum inhibitory concentration (MIC) values for all concentrations of CSA-44 and CSA-131 against S. aureus ranged between 2.50 and 5.00 µg/mL. Inhibitory action against C. albicans was found to be most pronounced in CSA-131 and CSA-44. The 0.2% of CSA-44 yielded the highest minimum bactericidal concentration (MBC) value of 5.00 µg/mL against S. aureus. The 1xMIC of CSA-44 (0.2%) decreased the bacterial load against E. faecalis at 3 h, even though the same effect was recorded at 6 h against S. aureus. CSA-44 and CSA-131 prevented the growth at 1.5xMIC at 3 h, whereas 1xMIC concentration inhibited the growth at 6 h for all tested microorganisms. The lowest viability was observed with CSA-131 (0.2% 100%), whereas CSA-44 shows lower toxicity than CSA-131 at the same dose. This study provides the first comparative evaluation of the antibacterial, antifungal, and cytotoxic properties of CSA-44 and CSA-131 against clinically relevant endodontic pathogens, offering novel insight into the therapeutic potential of ceragenins in dental applications.
Indexed as
Identifiers
41452448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.